BCP (5 [261], 25, and 50 [307] mg/kg p.o.)can also reduce symptom severity and associated inflammatory markers in the EAE model, as can dual CB2/PPARγ agonist VCE-004.8 (10 mg/kg i.p.)(also known as Etrinabdione, see Section 7.2 and Table 3) in two models of MS, EAE, and TMEV [308]. Here, CNR2 is linked to myeloid sarcoma.